• Gencurix corrected its business suspension filing to reflect a Seoul Administrative Court stay of NECA’s notice through 30 days post verdict.
• The earlier disclosure had said the stay was only temporary through Oct. 12, 2026.
• The suspension covers its domestic GenesWell BCT breast cancer prognosis testing service, representing KRW 5.88 billion, or 77.91%, of 2025 revenue.
• The company still expects to update the market when the court rules on the underlying lawsuit.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gencurix Inc. published the original content used to generate this news brief via DART, the regulatory disclosure system operated by the South Korea Financial Supervisory Service (FSS) (Ref. ID: 20261007000277), on October 07, 2026, and is solely responsible for the information contained therein.